A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine- tositumomab
Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg, Michael Leblanc, Myron S. Czuczman, Mark Kaminski, Rita M. Braziel, Catherine Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker R. Dakhil, Thomas P. Miller, Richard I. Fisher
Dive into the research topics of 'A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine- tositumomab'. Together they form a unique fingerprint.